Intravitreal Dexamethasone Implant as an alternative to systemic steroids as prophylaxis for Uveitic Cataract Surgery: A randomised trial

POSTOPERATIVE OUTCOMES FOLLOWING PROPHYLACTIC INTRAVITREAL DEXAMETHASONE IMPLANT(OZURDEX) VERSUS ORAL STEROIDS ALONGWITH CATARACT SURGERY: A RANDOMIZED CLINICAL TRIAL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/08/009444

Enrollment

Registered

2017-08-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with intermediate or posterior uveitis and cataract scheduled for cataract surgery Health Condition 2: H309- Unspecified chorioretinal inflammation

Interventions

Intervention1: INTRAVITREAL DEXAMETHASONE IMPLANT(OZURDEX, ALLERGAN, IRVINE, CA): An implant used both to treat uveitis and as prophylaxis under recurrent uveitis. Dose-750mg. Single injection. No rea

Eligibility

Inclusion criteria

Inclusion criteria: Patients >18 years with 1) controlled intermediate or posterior uveitis and 2)cataract will be randomized to receive either intravitreal dexamethasone implant or systemic steroids as prophylaxis against recurrent inflammation.

Exclusion criteria

Exclusion criteria: 1) Ocular/Systemic contraindications to steroids 2) Complicated cataract surgery 3) Attrition

Design outcomes

Secondary

Measure	Time frame
CHANGES IN CENTRAL SUBFIELD THICKNESS ON OCT, IF ANYTimepoint: EVERY MONTH FOR 6 MONTHS AFTER INTERVENTION	—

Primary

Measure	Time frame
Change in visual acuity intra and inter group comparison on Change in retinal thickness on OCT both intra and intergroup comparisonTimepoint: Every month for 6 months for all outcomes	—

Countries

India

Contacts

Public ContactAditya Sudhalkar

Raghudeep Eye Clinic

adityasudhalkar@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026